Molecule of the Month: Angiotensin and Blood Pressure

Many medications for controlling high blood pressure inhibit the action of the peptide hormone angiotensin.

Signaling pathway of angiotensin. The cell membrane is shown schematically in gray.
Signaling pathway of angiotensin. The cell membrane is shown schematically in gray.
Download high quality TIFF image
Healthy blood pressure requires a delicate balance: the pressure needs to be high enough to circulate blood throughout the body, but not so high that it causes damage. Our bodies constantly monitor blood pressure and make changes if it gets out of the optimal range. The hormone angiotensin plays a central role in this control. It is released when blood pressure needs to be increased. It circulates through the body and has many effects, including constriction of blood vessels and making us feel thirsty.

Sending Signals

Angiotensin performs its job in several steps. It is made by liver cells as a large inactive precursor called angiotensinogen, which is released into the bloodstream when needed. The small protease renin is released concurrently from the kidneys and it trims angiotensinogen to a small decapeptide, called angiotensin I. Angiotensin I is then clipped by ACE (angiotensin-converting enzyme), removing two more amino acids to form the octapeptide angiotensin II. Angiotensin II is the active hormone, binding to receptors on cell surfaces throughout the body and launching many processes that control flow of water and salt, releasing additional hormones, and contracting blood vessels.

Angiotensin in Action

We can explore the molecular details of all of these molecules in the PDB archive. As seen in the interactive JSmol below, we can compare structures of the inactive precursor of renin (PDB ID 3vcm) with the active form as it is clipping angiotensinogen (PDB ID 2x0b). ACE is a membrane-bound enzyme with two similar protein-cutting domains that cleave angiotensin I as well as other peptide hormones. The full structure is shown here from a computed structure model (AF_AFP12821F1), and many experimental structures of the individual domains are available in the archive. Structures are also available for angiotensin I (PDB ID 1n9u) and the receptor bound to angiotensin II (PDB ID 6os0).

Complex of one ACE domain (blue) with the blood pressure drug lisinopril (yellow).
Complex of one ACE domain (blue) with the blood pressure drug lisinopril (yellow).
Download high quality TIFF image

Blood Pressure Medication

By understanding the structures of proteins involved in the angiotensin signaling pathway, researchers have developed drugs to modify their action and lower blood pressure, if needed. The widely-used drug lisinopril is shown here, bound in the active site of the angiotensin-cutting domain of ACE (PDB ID 1o86). Because blood pressure management is so important for health, other drugs have been developed to block the action of all the other steps of the signaling pathway. For example, the interactive JSMol below includes a drug that blocks the action of renin.

Exploring the Structure

Renin in Action

Three structures reveal different states of renin. PDB ID 3vcm includes prorenin, the inactive form that is created inside kidney cells. After synthesis, the propeptide is clipped off and activated renin is stored safely in vesicles until it’s needed. PDB ID 2x0b shows how renin binds to angiotensinogen, positioning it perfectly so that it can cleave it in the proper place. PDB ID 2v0z shows the drug Aliskiren bound in the active site, blocking the action of renin and helping to reduce blood pressure.

To explore these structures in more detail, click on the JSmol tab for an interactive view.

Topics for Further Discussion

  1. The enzyme ACE2 is similar to the ACE described here. ACE2 makes additional cleavages in angiotensin and is used by SARS-CoV-2 as its receptor for infection. You can explore its structure in PDB ID 6m17.
  2. You can use the Pairwise Structure Alignment tool to compare the two domains of ACE, using PDB ID 1o86 and 2c6n.

References

  1. Fountain, J. H., Kaur, J., Lappin, S. L. (2024) Physiology, Renin Angiotensin System. StatPearls www.ncbi.nlm.nih.gov/books/NBK470410/
  2. 6os0: Wingler, L.M., Skiba, M.A., McMahon, C., Staus, D.P., Kleinhenz, A.L.W., Suomivuori, C.M., Latorraca, N.R., Dror, R.O., Lefkowitz, R.J., Kruse, A.C. (2020) Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR. Science 367: 888-892
  3. Bernstein, K.E., Ong, F.S., Blackwell, W.L.B., Shah, K.H., Giani, J.F., Gonzalez-Villalobos, R.A., Shen, X.Z., Fuchs, S. (2013) A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev 65: 1-46
  4. 2x0b: Zhou, A., Carrell, R.W., Murphy, M.P., Wei, Z., Yan, Y., Stanley, P.L., Stein, P.E., Pipkin, F.B., Read, R.J.(2010) A redox switch in angiotensinogen modulates angiotensin release. Nature 468: 108
  5. 1o86: Natesh, R., Schwager, S.L.U., Sturrock, E.D., Acharya, K.R. (2003) Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 421: 551
  6. 1n9u: Spyroulias, G.A., Nikolakopoulou, P., Tzakos, A., Gerothanassis, I.P., Magafa, V., Manessi-Zoupa, E., Cordopatis, P. (2003) Comparison of the solution structures of angiotensin I & II. Implication for structure-function relationship. Eur J Biochem 270: 2163-2173
  7. 2v0z: Rahuel, J., Rasetti, V., Maibaum, J., Rueger, H., Goschke, R., Cohen, N.C., Stutz, S., Cumin, F., Fuhrer, W., Wood, J.M., Grutter, M.G. (2000) Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 7: 493-504

October 2024, David Goodsell

http://doi.org/10.2210/rcsb_pdb/mom_2024_10
About Molecule of the Month
The RCSB PDB Molecule of the Month by David S. Goodsell (The Scripps Research Institute and the RCSB PDB) presents short accounts on selected molecules from the Protein Data Bank. Each installment includes an introduction to the structure and function of the molecule, a discussion of the relevance of the molecule to human health and welfare, and suggestions for how visitors might view these structures and access further details.More